News & Media / Opinions & Features

Trump, Interest Rates, And Biotech Investing In 2017

December 23, 2016

We are heading into 2017 with a great deal of uncertainty, but if President-elect Trump governs the nation as he said he would – unconventionally and unpredictably – we may experience a significant uptick in market volatility as foreign governments and global markets react to America’s new stance in the world.

Continue Reading

WBB Securities Co-Manages $25 Million Public Offering for TetraLogic

May 1, 2015

WBB Securities is acting as co-manager to a transaction for TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology.

Continue Reading

WBB Securities Co-Manages $84 Million Public Offering for Omeros Corporation

February 4, 2015

WBB Securities acted as co-manager to a transaction for Omeros Corporation in an underwritten public offering that closed on February 3, 2015.

Continue Reading

Obama’s New Healthcare Proposal: A Precise Vision Or A Political Football

February 4, 2015

When President Obama unveiled his Precision Medicine Initiative, he declared a two-fold challenge.

Continue Reading